SCHEMBL15037085

SCHEMBL15037085

CC(C)(C)c1ccc(-c2cnc(-c3ccc(C[C@H](NC(=O)c4ccc(C(C)(C)C)s4)C(=O)N[C@@H](CC(=O)O)C(=O)O)cc3)nc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIFC1 Q9BW19 2/20 0.38
▸ PTPN1 P18031 3/20 0.37
▸ ACE P12821 5/20 0.37
▸ MME P08473 4/20 0.37
▸ CPA1 P15085 4/20 0.37
▸ ACE2 Q9BYF1 4/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KLKB1 P03952 2/20 0.37
▸ PRSS1 P07477 3/20 0.37
▸ TMPRSS15 P98073 3/20 0.37
▸ MCL1 Q07820 1/20 0.36
▸ ADCY6 O43306 1/20 0.36
▸ ADCY3 O60266 1/20 0.36
▸ ADCY9 O60503 1/20 0.36
▸ ADCY5 O95622 1/20 0.36
▸ ADCY8 P40145 1/20 0.36
▸ GCGR P47871 1/20 0.36
▸ ADCY7 P51828 1/20 0.36
▸ ADCY2 Q08462 1/20 0.36
▸ ADCY1 Q08828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15037234 1.00 KIFC1 (0.38) KIFC1PTPN1ACEMMECPA1
SCHEMBL15037350 0.93 MCL1 (0.38) KIFC1ACEMMECPA1ACE2
SCHEMBL15037230 0.93 MCL1 (0.38) KIFC1ACEMMECPA1ACE2
SCHEMBL22384128 0.93 MCL1 (0.38) KIFC1ACEMMECPA1ACE2
SCHEMBL22384390 0.93 KLKB1 (0.39) KIFC1ACEMMECPA1ACE2
SCHEMBL15037409 0.93 KLKB1 (0.39) KIFC1ACEMMECPA1ACE2
SCHEMBL22449186 0.92 HPGD (0.41) KIFC1ADCY6ADCY3ADCY9ADCY5
SCHEMBL15037080 0.92 HPGD (0.41) KIFC1ADCY6ADCY3ADCY9ADCY5
SCHEMBL15037083 0.92 HPGD (0.41) KIFC1ADCY6ADCY3ADCY9ADCY5
SCHEMBL17834867 0.92 KIFC1 (0.43) KIFC1PTPN1ACEMMECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-2791112-B1 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES CELGENE INT II SÀRL (CH) 2020-09-23 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885PTPN1 236/4885ACE 3137/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885PTPN1 236/4885ACE 3137/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885PTPN1 236/4885ACE 3137/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4720/4885PTPN1 271/4885ACE 3129/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4720/4885PTPN1 271/4885ACE 3129/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR KIFC1 4749/4885PTPN1 258/4885ACE 2924/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR KIFC1 4749/4885PTPN1 258/4885ACE 2924/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KIFC1 4738/4885PTPN1 236/4885ACE 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback